163 related articles for article (PubMed ID: 24533578)
21. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
22. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
23. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
24. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
25. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
26. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
28. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
29. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
30. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
32. FDA approves vemurafenib for treatment of metastatic melanoma.
Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
[No Abstract] [Full Text] [Related]
33. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
34. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.
Viarisio D; Müller-Decker K; Hassel JC; Alvarez JC; Flechtenmacher C; Pawlita M; Gissmann L; Tommasino M
J Invest Dermatol; 2017 Jan; 137(1):261-264. PubMed ID: 27650607
[No Abstract] [Full Text] [Related]
35. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
36. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
37. BRAF inhibitor-induced neutrophilic dermatoses: a bitter-"sweet" scenario.
Heymann WR
Skinmed; 2015; 13(2):132-4. PubMed ID: 26137740
[No Abstract] [Full Text] [Related]
38. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
40. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
